Overview

A Study of MabThera/Rituxan (Rituximab) in Patients With Non-Bulky Follicular Non-Hodgkin's Lymphoma

Status:
Completed
Trial end date:
2006-02-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy and safety of MabThera/Rituxan (rituximab) in treatment-naive patients with non-bulky follicular non-Hodgkin's lymphoma. The anticipated time on study treatment is 3 months.
Phase:
Phase 2
Details
Lead Sponsor:
Hoffmann-La Roche
Treatments:
Rituximab